


# PRODUCT INFORMATION



## Etofibrate

Item No. 21022

**CAS Registry No.:** 31637-97-5  
**Formal Name:** 3-pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl ester  
**Synonym:** Nicotinic Acid  
**MF:** C<sub>18</sub>H<sub>18</sub>ClNO<sub>5</sub>  
**FW:** 363.8  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 222, 263 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Etofibrate is supplied as a crystalline solid. A stock solution may be made by dissolving the etofibrate in the solvent of choice, which should be purged with an inert gas. Etofibrate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of etofibrate in ethanol and DMSO is approximately 80 mg/ml and approximately 50 mg/ml in DMF.

Etofibrate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, etofibrate should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Etofibrate has a solubility of approximately 0.1 mg/ml in a 1:5 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Etofibrate is a combination of niacin and clofibrate (Item No. 10956) that acts as a hypolipidemic agent.<sup>1</sup> *In vivo*, etofibrate decreases plasma cholesterol and triglyceride concentrations and increases bile cholesterol content in rats.<sup>1,2</sup> It also decreases thromboxane formation, platelet aggregation, and plasma viscosity and inhibits neointima formation in a carotid artery balloon injury rat model.<sup>3</sup> Formulations containing etofibrate have been used to treat hyperlipidemia.

### References

1. Bocos, C., Orozco, E., Castro, M., *et al.* Effect of etofibrate on bile production in the normolipidemic rat. *Gen. Pharmacol.* **26(3)**, 537-542 (1995).
2. Herrera, E., Lasunción, M.A., Castro, M., *et al.* Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. *Biochim Biophys. Acta.* **963(1)**, 42-52 (1988).
3. Kinscherf, R., Metz, J., and Wülfroth, P. Etofibrate suppresses neointima formation of the ballooned common carotid artery of rats. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **352(4)**, 424-428 (1995).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM